Berberine

Generic Name: Berberine

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₈NO_₄

CAS Number: 2086-83-1

Unique Ingredient Identifier: 0I8Y3P32UF

Background: An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

Indication: 主要用于志贺菌属、霍乱弧菌等敏感病原菌所致的胃肠炎、细菌性痢疾等肠道感染。

外用用于治疗敏感细菌引起的宫颈糜烂。

Clinical Trials

Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine

Phase 2

Conditions: Hyperlipidemia

Interventions: Drug: Berberine
Drug: Placebo

First Posted Date: 2025-01-20

Last Posted Date: 2025-01-20

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 100

Registration Number: NCT06782646

Locations: 🇭🇰
School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong

6-year Follow-up Data After the Berberine Intervention Trial

Recruiting

Conditions: Colorectal Adenoma
Colorectal Cancer Control and Prevention
Colorectal Polyps

Interventions: Drug: Berberine Hydrochloride
Drug: Placebo

First Posted Date: 2024-10-07

Last Posted Date: 2024-10-07

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 891

Registration Number: NCT06629051

Locations: 🇨🇳
Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China

Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection
Chronic Gastritis

Interventions: Drug: esomeprazole
Drug: Bismuth
Drug: Berberine
Drug: Amoxicillin
Drug: Minocycline
Drug: clarithromycin

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 548

Registration Number: NCT06603688

Locations: 🇨🇳
Xijing Hosipital of Digestive Disease, Xian, Shaanxi, China

Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication

Phase 4

Not yet recruiting

Conditions: Helicobacter Pylori Infection
Chronic Gastritis

Interventions: Drug: Berberine
Drug: Bismuth
Drug: Vonoprazan
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Esomeprazole

First Posted Date: 2024-07-23

Last Posted Date: 2024-07-23

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 558

Registration Number: NCT06514274

Locations: 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

Berberine on the Secretion of Incretin

Early Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Berberine Chloride
Drug: Placebo

First Posted Date: 2023-07-17

Last Posted Date: 2023-07-17

Lead Sponsor: Beijing Tongren Hospital

Target Recruit Count: 16

Registration Number: NCT05947370

Locations: 🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Hao Wang, Beijing, China

Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

Phase 4

Not yet recruiting

Conditions: Abdominal Obesity
PreDiabetes
Hypertension
Dyslipidemias

Interventions: Drug: Berberine plus lifestyle intervention
Behavioral: Placebo plus lifestyle intervention

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-08

Lead Sponsor: China National Center for Cardiovascular Diseases

Target Recruit Count: 6500

Registration Number: NCT05749874

Locations: 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, Beijing, China

A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects.

Not Applicable

Recruiting

Conditions: Prediabetes

Interventions: Drug: Berberine
Drug: Akkermansia muciniphila
Drug: Berberine Placebo
Drug: AKK Placebo

First Posted Date: 2023-02-09

Last Posted Date: 2025-05-01

Lead Sponsor: Yu Chen

Target Recruit Count: 90

Registration Number: NCT05720299

Locations: 🇨🇳
The Seventh Affiliated Hospital of Southern Medical University, Foshan, Guangdong, China

Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

Phase 4

Completed

Conditions: Obesity, Abdominal
NAFLD
Obesity

Interventions: Behavioral: Placebo plus lifestyle intervention
Drug: Berberine plus lifestyle intervention

First Posted Date: 2022-12-13

Last Posted Date: 2025-01-29

Lead Sponsor: China National Center for Cardiovascular Diseases

Target Recruit Count: 337

Registration Number: NCT05647915

Locations: 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, Beijing, China

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

Phase 4

Not yet recruiting

Conditions: Metabolic Syndrome

Interventions: Behavioral: Healthy lifestyle intervention
Drug: Berberine

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-03

Lead Sponsor: Tang Yida

Target Recruit Count: 5200

Registration Number: NCT05105321

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication

Phase 4

Completed

Conditions: Helicobacter Pylori Infection
Chronic Gastritis

Interventions: Drug: Berberine
Drug: Vonoprazan
Drug: Rabeprazole
Drug: Amoxicillin
Drug: Bismuth
Drug: Clarithromycin

First Posted Date: 2021-08-20

Last Posted Date: 2023-01-31

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 300

Registration Number: NCT05014334

Locations: 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy